Understanding Primary Pigmented Nodular Adrenocortical Disease (PPNAD)
At a Glance
PPNAD is a rare condition in which both adrenal glands usually develop tiny nodules that make too much cortisol without the brain's usual ACTH signal. Because symptoms and scans can be subtle, diagnosis may require repeated hormone tests, imaging, PRKAR1A testing, and evaluation for Carney Complex.
Primary Pigmented Nodular Adrenocortical Disease (PPNAD) is an exceptionally rare cause of Cushing’s syndrome, a condition where the body produces too much of the hormone cortisol [1][2]. Cushing’s syndrome has several causes, including exposure to prescribed steroid medications. While some endogenous cases—specifically called Cushing’s disease—are caused by a pituitary tumor in the brain, PPNAD is ACTH-independent [2]. This means the adrenal glands—the two small, hat-shaped organs sitting on top of your kidneys—act on their own, pumping out cortisol without receiving the “start” signal (ACTH) from the brain [3].
A Rare and Subtle Journey
Finding a diagnosis for PPNAD can be a long and frustrating journey because the disease is extremely rare and its symptoms are often “quiet.” While some people have clear symptoms of cortisol excess, others have cyclic Cushing’s syndrome, where cortisol levels rise and fall in waves [4]. This can lead to “normal” test results one day and high results the next, which may cause doctors to initially overlook the condition [4][5].
In children, the clues are often different than in adults. A child might experience growth failure (height slowing down) while simultaneously gaining weight, a pattern that is a strong indicator of hormone trouble [6][7]. Because the disease is so uncommon, you may find that many doctors have never encountered it before [8][9].
The Biology of PPNAD
The name of the condition describes exactly what is happening inside the adrenal glands:
- Primary: The problem starts in the adrenal glands themselves.
- Pigmented: The tiny growths are often dark brown, black, or yellow because they contain a pigment called lipofuscin [10].
- Nodular: The glands develop multiple tiny lumps or micronodules, usually only 1 to 4 millimeters in size [10].
- Adrenocortical: The nodules grow in the outer layer (cortex) of the adrenal gland.
The biological “engine” behind PPNAD is usually a mutation in the PRKAR1A gene [9]. Think of the PRKAR1A gene as the instructions for a “brake” on your adrenal cells’ activity. Specifically, it creates a protein called the R1-alpha regulatory subunit [11]. This subunit’s job is to hold onto another protein, Protein Kinase A (PKA), and keep it from working until it is needed [11][12].
In PPNAD, the mutation breaks that “brake.” Without a functional R1-alpha subunit to hold it back, the PKA protein becomes overactive [12][13]. This overactive PKA signals the adrenal cells to grow into nodules and constantly manufacture cortisol, regardless of what the rest of the body needs [14][15].
The Connection to Carney Complex
PPNAD does not always happen in isolation. It is frequently one piece of a larger puzzle called Carney Complex (CNC), a genetic syndrome that can affect several different parts of the body [9].
The association varies by population and whether clinical or genetic criteria are used, but a significant portion of people with PPNAD also have features of Carney Complex [9][5]. In specialized clinics that focus on genetics, the observed overlap can be even higher [4].
Because of this strong link, a diagnosis of PPNAD usually prompts doctors to look for other signs of Carney Complex, which can include:
- Lentigines: Small, dark freckle-like spots on the lips, eyelids, or inside the mouth [4].
- Myxomas: Non-cancerous tumors that can grow in the heart, skin, or other tissues [4].
- Endocrine tumors: Growths in other hormone-producing glands, like the thyroid or pituitary [4].
How PPNAD is Identified
Diagnosing PPNAD requires a “detective” approach, combining several types of evidence:
- Biochemical Evidence: Doctors look for high cortisol levels and low or “suppressed” ACTH levels [3]. One test specialists may use is a paradoxical rise in cortisol during a Liddle test (a multi-day dexamethasone suppression test); while most adrenal tumors stop producing cortisol during this test, PPNAD nodules can produce even more [16][17].
- Imaging Challenges: A standard CT scan of the adrenal glands may look completely normal in some patients with PPNAD because the nodules are so small [5][18]. In other cases, the glands may show a “beaded” appearance or multiple tiny lumps [19][18].
- Genetic Testing: Testing for the PRKAR1A mutation and genetic counseling are important steps [4]. If a pathogenic germline mutation is found, it strongly supports Carney Complex and provides important information for family members, who may also need to be screened [4][20]. However, PPNAD can be isolated, some affected patients have no detectable variant on routine testing, and a variant of uncertain significance does not establish a diagnosis.
Understanding that PPNAD is a bilateral disease—meaning it typically affects both adrenal glands—is crucial for planning treatment, as it distinguishes this condition from a single, isolated adrenal tumor [21][22].
Common questions in this guide
What is PPNAD, and how does it cause Cushing syndrome?
What symptoms might PPNAD cause in a child?
Why can cortisol tests be normal if someone has PPNAD?
What does a low ACTH result mean in PPNAD?
Can a CT scan miss PPNAD?
Why are PRKAR1A testing and Carney Complex screening discussed?
What is the Liddle test, and what can it show?
Get notified when new evidence is published on pigmented nodular adrenocortical disease, primary, 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (22)
- 1
Unilateral Adrenalectomy Could Be a Valid Option for Primary Nodular Adrenal Disease: Evidence From Twins.
Kyrilli A, Lytrivi M, Bouquegneau MS, et al.
Journal of the Endocrine Society 2019; (3(1)):129-134 doi:10.1210/js.2018-00261.
PMID: 30591956 - 2
ACTH independent Cushing's syndrome: Diagnosis and etiology.
Ortiz-Flores AE
Vitamins and hormones 2026; (132()):79-92 doi:10.1016/bs.vh.2026.02.001.
PMID: 42236016 - 3
Primary pigmented nodular adrenocortical disease (PPNAD): single centre experience.
Memon SS, Thakkar K, Patil V, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(4)):391-397.
PMID: 30875328 - 4
Integrated clinical-genetic-pathological analysis expands the phenotypic and molecular spectrum of PPNAD across carney complex and isolated forms.
Kuhn AW, Lerario AM, Charchar HL, et al.
European journal of endocrinology 2026; (195(2)):217-228 doi:10.1093/ejendo/lvag137.
PMID: 42543523 - 5
Hormonal, Radiological, NP-59 Scintigraphy, and Pathological Correlations in Patients With Cushing's Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD).
Vezzosi D, Tenenbaum F, Cazabat L, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(11)):4332-8 doi:10.1210/jc.2015-2174.
PMID: 26390100 - 6
Preventing Cushing Syndrome: Adrenalectomy in PDE11A-Positive Primary Pigmented Nodular Adrenocortical Disease.
Carling T, LaRue M, Lenz AM, et al.
JCEM case reports 2026; (4(2)):luaf329 doi:10.1210/jcemcr/luaf329.
PMID: 41694449 - 7
Familial Forms of Cushing Syndrome in Primary Pigmented Nodular Adrenocortical Disease Presenting with Short Stature and Insidious Symptoms: A Clinical Series.
Navarro Moreno C, Delestienne A, Marbaix E, et al.
Hormone research in paediatrics 2018; (89(6)):423-433 doi:10.1159/000488761.
PMID: 29909407 - 8
Carney complex due to a novel pathogenic variant in the PRKAR1A gene - a case report.
Ferreira SH, Costa MM, Rios E, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(2)):197-202.
PMID: 30699069 - 9
The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.
Sun J, Ding L, He L, et al.
Frontiers in endocrinology 2024; (15()):1356870 doi:10.3389/fendo.2024.1356870.
PMID: 39006359 - 10
Cushing Syndrome in Carney Complex: Clinical, Pathologic, and Molecular Genetic Findings in the 17 Affected Mayo Clinic Patients.
Lowe KM, Young WF, Lyssikatos C, et al.
The American journal of surgical pathology 2017; (41(2)):171-181 doi:10.1097/PAS.0000000000000748.
PMID: 27875378 - 11
Noncanonical protein kinase A activation by oligomerization of regulatory subunits as revealed by inherited Carney complex mutations.
Jafari N, Del Rio J, Akimoto M, et al.
Proceedings of the National Academy of Sciences of the United States of America 2021; (118(21)) doi:10.1073/pnas.2024716118.
PMID: 34006641 - 12
Genetics of micronodular adrenal hyperplasia and Carney complex.
Tirosh A, Valdés N, Stratakis CA
Presse medicale (Paris, France : 1983) 2018; (47(7-8 Pt 2)):e127-e137 doi:10.1016/j.lpm.2018.07.005.
PMID: 30093212 - 13
A Novel Missense PRKAR1A Variant Causes Carney Complex.
Kim B, Jang HN, Chae KS, et al.
Endocrinology and metabolism (Seoul, Korea) 2022; (37(5)):810-815 doi:10.3803/EnM.2022.1544.
PMID: 36193716 - 14
Update of Genetic and Molecular Causes of Adrenocortical Hyperplasias Causing Cushing Syndrome.
Berthon A, Bertherat J
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(8)):598-606 doi:10.1055/a-1061-7349.
PMID: 32097969 - 15
PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors.
Berthon AS, Szarek E, Stratakis CA
Frontiers in cell and developmental biology 2015; (3()):26 doi:10.3389/fcell.2015.00026.
PMID: 26042218 - 16
Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome.
Chen S, Li R, Lu L, et al.
Endocrine 2018; (59(1)):183-190 doi:10.1007/s12020-017-1436-9.
PMID: 29094256 - 17
Update on primary micronodular bilateral adrenocortical diseases.
Maillet M, Bourdeau I, Lacroix A
Current opinion in endocrinology, diabetes, and obesity 2020; (27(3)):132-139 doi:10.1097/MED.0000000000000538.
PMID: 32209819 - 18
Challenging Diagnostic Workup of a 22-year-old Patient With Primary Pigmented Nodular Adrenocortical Disease.
Wernig J, Pilz S, Trummer C, et al.
JCEM case reports 2024; (2(10)):luae174 doi:10.1210/jcemcr/luae174.
PMID: 39355138 - 19
Bilateral Adrenocortical Nodular Disease and Cushing's Syndrome.
Bouys L, Violon F, Louiset E, et al.
The Journal of clinical endocrinology and metabolism 2024; (109(10)):2422-2432 doi:10.1210/clinem/dgae419.
PMID: 38888184 - 20
Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation.
Zhang CD, Pichurin PN, Bobr A, et al.
Endocrinology, diabetes & metabolism case reports 2019; (2019()).
PMID: 30897549 - 21
Bilateral macronodular and micronodular hyperplasia: Biochemical, radiological and genetic diagnosis.
Navas-Moreno V, Sager-La Ganga C, Tapia-Sanchiz MS, et al.
Vitamins and hormones 2026; (132()):93-126 doi:10.1016/bs.vh.2026.02.002.
PMID: 42236017 - 22
Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease.
Araujo-Castro M, Marazuela M
Frontiers in endocrinology 2022; (13()):913253 doi:10.3389/fendo.2022.913253.
PMID: 35992106
This page is for educational information about PPNAD and does not replace medical advice. An endocrinologist and genetic counselor can interpret your hormone tests, imaging, and PRKAR1A results in the context of your health and family history.